Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
Rituximab, a chimeric mouse-human monoclonal antibody directed to the CD20 antigen expressed on pre-B lymphocytes and mature lymphocytes, causes a profound B-cell depletion. Due to its peculiar characteristics, this drug has been used to treat oncohaematological diseases, B cell-related autoimmune d...
Main Authors: | Evangelista Sagnelli, Mariantonietta Pisaturo, Caterina Sagnelli, Nicola Coppola |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/945950 |
Similar Items
-
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
by: Nicola Coppola, et al.
Published: (2014-01-01) -
Epidemiology and management of hepatitis C virus infections in immigrant populations
by: Nicola Coppola, et al.
Published: (2019-03-01) -
Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
by: Coppola Nicola, et al.
Published: (2012-12-01) -
HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
by: Caterina Sagnelli, et al.
Published: (2021-02-01) -
Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression.
by: Nicola Coppola, et al.
Published: (2013-01-01)